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Background: A three-dimensional electrocardiographic (ECG) metric, the sum absolute QRST
integral (SAI QRST), predicts ventricular arrhythmias in heart failure (HF) patients with implantable
cardioverter defibrillator and mechanical response to cardiac resynchronization therapy. We
hypothesized that there is an association between patient-specific changes in SAI QRST and
myocardial injury as measured by high-sensitivity troponin I (hsTnI).
Methods: Sum absolute integral QRST on resting 12-lead ECG and hsTnI were measured
simultaneously, every 3 hours, and during 12-hour observation period in a prospective cohort of
emergency department patients (n = 398; mean age 57.8  13.2 years; 54% female, 64% black),
diagnosed with acute coronary syndrome (ACS, n = 28), acutely decompensated HF (acute
decompensated heart failure, n = 35), cardiac non-ACS (n = 19), or noncardiac condition
(n = 316). Random-effects linear regression analysis assessed the association of SAI QRST and
myocardial injury, with adjustment for demographics (age, sex, race), prevalent cardiovascular
disease (myocardial infarction, history of revascularization, stroke, and HF), risk factors (diabetes,
smoking, hypercholesterolemia, hypertension, and cocaine use), and left bundle branch block.
Results: Within the entire cohort, SAI QRST decreased by 3 (95%CI 5 to 1) mV*ms every
3 hours. A 10-fold increase in hsTnI was associated with a 7.7 (0.6–14.9) mV*ms increase in SAI
QRST. In the subgroup of acutely decompensated HF patients (n = 35), a 10-fold increase in
hsTnI was associated with a 61.0 (5.9–116.1) mV*ms increase in SAI QRST.
Conclusion: Patient-specific time-varying changes in the surface ECG scalar measure of global
electrical heterogeneity, as measured by SAI QRST, and in myocardial injury as measured by
hsTnI, are independently and directly associated with each other, likely reflecting a common
underlying mechanism.
Ann Noninvasive Electrocardiol 2017;22(1):e12379, DOI: 10.1111/anec.12379
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Heart failure (HF) is a debilitating condition that
is associated with high morbidity, mortality, and
healthcare resource utilization.1 HF is associated
with a substantial risk of ventricular arrhythmias
and sudden cardiac death (SCD).2 Accurate risk
stratification is essential for appropriate clinical
management of HF patients. An electrocardio-
graphic (ECG) measure of global electrical
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heterogeneity and electrical remodeling, the sum
absolute QRST integral (SAI QRST), which can be
easily derived from a routine clinical 12-lead
ECG, has been shown associated with several
clinically important outcomes in HF, including
mechanical response to cardiac resynchronization
therapy (CRT),3 HF hospitalizations,4 ventricular
tachyarrhythmias,5, 6 and SCD.4
Across the spectrum of HF conditions, acute
decompensated heart failure (ADHF) is character-
ized by the highest mortality.7, 8 Biomarker of
myocardial injury Troponin has been shown to be
associated with increased mortality9 in ADHF.
High-sensitivity cardiac troponin (hsTn) recently
emerged as a sensitive biomarker of a dynamic
myocardial injury. In hospitalized ADHF patients,
baseline, peak, and peak change hsTnT were
associated with worse cardiovascular mortality10
postdischarge.
Sudden cardiac death is associated with under-
lying subclinical myocardial injury.11 Risk of SCD
is dynamic, which could reflect remodeling and
dynamic subclinical myocardial injury. In MADIT-
II study, SAI QRST correlated with the time passed
since myocardial infarction (MI), and predicted
both arrhythmic (SCD, sustained ventricular tach-
yarrhythmias) and HF outcomes.4 However,
whether dynamic changes in the electrophysiologi-
cal substrate, as quantified by the surface ECG, are
a reflection of underlying dynamic myocardial
injury remains unclear. In this study, we examined
the association between ECG marker SAI QRST
and myocardial injury as measured by a high-sensi-
tivity troponin I (hsTnI) assay. We hypothesized
that the dynamic changes in the level of hsTnI are
associated with the dynamic changes in the level
of SAI QRSTon the surface ECG.
METHODS
We conducted an ancillary study of a prospective
observational cohort12 of emergency department
(ED) patients evaluated for acute coronary syn-
drome (ACS). The study was approved by the
institutional review board, and all participants
provided written informed consent. The original
cohort12 enrolled consecutive patients with sus-
pected ACS of age 25 or older, who presented to
the Johns Hopkins Hospital (JHH) ED with nondi-
agnostic initial ECG, chief complaints of chest
pain or shortness of breath, and had cardiac tro-
ponin I (cTnI) ordered by treating clinicians.
Patients with overt ST-elevation myocardial infarc-
tion (STEMI) or non–ST-elevation myocardial
infarction (NSTEMI) at the time of initial presenta-
tion in the ED were excluded. Serial ECG and
hsTnI measurements were performed every
3 hours during a period of observation in the ED.
The Abbott Laboratories (Abbott Park, IL)
research-use ARCHITECT STATassay was used for
hsTnI measurements, as previously described.12,13
A diagnosis of acute coronary syndrome was
the primary outcome of the parent cohort study.12
Final clinical diagnoses were adjudicated by an
independent end points adjudication committee
comprised five board-certified ED physicians and
two board-certified cardiologists. As previously
described,12 each study participant was finally
diagnosed with one of the following conditions:
(1) ACS, which included acute MI or unstable
angina; (2) cardiac non-ACS diagnosis, which
included myocarditis, pericarditis, valvular disor-
ders, and cardiac arrhythmias; (3) ADHF; (4) non-
cardiac volume overload; (5) pulmonary
embolism; and (6) other noncardiac condition.
In this ancillary study, we included participants
with (1) available serial digital resting ECG, and
(2) a final diagnosis of ACS, cardiac non-ACS,
ADHF, and noncardiac conditions. Digital ECGs
were available for custom ECG analysis only for
the parent cohort study participants who were
enrolled at the JHH ED from 16 January 2012 to
26 June 2012.13 Participants with a final diagnosis
of noncardiac volume overload and pulmonary
embolism were excluded. In addition, we
excluded participants with ventricular pacing on
12-lead ECG.
Serial digital resting 12-lead ECGs in sinus
rhythm were extracted from the hospitals ECG
MUSE database (GE Healthcare, Wauwatosa, WI,
USA) and transformed into three-dimensional
orthogonal XYZ ECGs by using an inverse Dower
transformation matrix.14 ECG analyses were per-
formed by investigators (AF and LGT) blinded to
participants clinical characteristics and final diag-
nosis. The median beat was used for analysis.
The absolute value of the area under the entire
QRST waveform was measured on each orthogo-
nal lead (X, Y, and Z). Absolute QRST integral
values on X, Y, and Z leads were then summed to
obtain SAI QRST as previously described.4–6,15
Statistical analysis was performed using STATA
14 (StataCorp LP, College Station, TX, USA). Cat-
egorical variables were compared by Pearsons
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chi-square test. HsTnI values were log-10-trans-
formed to normalize their distribution, prior to
inclusion in regression models. ANOVA with Bon-
ferroni correction for multiple comparisons was
used to compare continuous variables across four
clinical groups.
In order to determine whether the patient-spe-
cific time-varying changes in the SAI QRST are
associated with the patient-specific time-varying
hsTnI changes during 12-hour observation in the
ED, we conducted generalized least squares ran-
dom-effects linear regression analysis. Patient-spe-
cific time-varying hsTnI served as a predictor.
Patient-specific time-varying SAI QRST served as
an outcome. We performed Hausman test to
choose between the random-effect estimator (as-
suming that the unobserved time-invariant ran-
dom component is unrelated to the predictors)
and fixed-effect estimator (allowing the unob-
served random component to be related to the
predictors). In model 1, we adjusted for con-
founding demographic variables: age, sex, and
race. Model 2 included all variables in model 1,
as well as prevalent cardiovascular disease (prior
myocardial infarction (MI), prior revascularization
procedure (CABG or PCI), prior stroke, and HF).
Model 3 included all the model 2 variables and
known risk factors of cardiovascular disease
(hypercholesterolemia, smoking, diabetes, hyper-
tension, and cocaine use). With increasing com-
plexity of the models, it was difficult to guarantee
that unmeasured variables were not correlated
with predictors in the model. In order to correct
for endogeneity and simultaneity problems, in
model 4 we conjectured that left bundle branch
block (LBBB) was endogenous (i.e., correlated
with predictors and outcome (SAI QRST), but
uncorrelated with unobserved random variable)
and used prevalent cardiovascular disease and its
risk factors included in model 3 as instrumental
variables.
RESULTS
This ancillary study included 398 participants
(mean age 57.8  13.2 years; 215 (54%) female,
and 256 (64.3%) black). Clinical characteristics of
study participants are shown in Table 1. As
expected, ADHF patients had the highest rate of
HF history and LBBB on ECG. ACS patients had
the highest probability of having prior coronary
artery revascularization. Patients diagnosed with
a noncardiac condition were younger and had the
lowest probability of being admitted.
During the 12-hour observation period in ED,
SAI QRST was measured on average 3.2 times,
every 3 hours, and demonstrated fluctuations
(both increases and decreases) in 317 (80%) of
study participants. Overall mean SAI QRST was
122.8  55.8 mV*ms. There was no statistically
significant difference in baseline SAI QRST across
study groups (Table 1), although there was a
trend toward higher SAI QRST in ADHF. The
average individual SAI QRST across study partici-
pants ranged widely, from 40.5 to 433.7 mV*ms.
Figure 1 shows representative example of 12-lead
ECG in ADHF patient with slowly but steadily
decreasing values of both hsTnI and SAI QRST.
Figure 2 displays patient-specific changes in SAI
QRST and hsTnI over time for the whole study
population. Both population averaged and
patient-specific random-effect regression models
showed that within the entire cohort, SAI QRST
decreased by a mean of 3 mV*ms every 3 hours
(95% CI: from 5 to 1 mV*ms) during the 12-
hour study period.
Patient-specific analysis showed that SAI QRST
increased at all time points in 45 (11%) partici-
pants, decreased at all time points in 29 (7%) par-
ticipants, and did not change at all time points in
7 (2%) participants. The majority of study partici-
pants (80%) experienced fluctuations of SAI
QRST. The range of individual changes during 12-
hour ED observation time relative to the overall
mean SAI QRST was substantial (from reduction
by 93.3 mV*ms to the growth by 303.3 mV*ms).
Clinical characteristics of patients with different
SAI QRST dynamics during 12-hour ED observa-
tion period were remarkably similar (Table 2),
with few exceptions. Patients with steadily falling
SAI QRST were likely current cocaine users.
Patients with fluctuating SAI QRST were more
likely to have had prior coronary artery revascu-
larization.
Similar to SAI QRST, hsTnI was measured
every 3 hours (on average 2.4 times) during 12-
hour observation period in ED. Overall median
hsTnI was 7.2 (IQR 3.7–20.8) ng/L, which was
below the 99th% URL of this assay (34.2 ng/L for
males, 15.6 ng/L for females, and 26.2 ng/L over-
all). The average individual hsTnI across study
participants ranged from zero to 6,782 ng/L.
Dynamic changes in hsTnI had a similar pattern,
as compared to the dynamic changes in SAI
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QRST (Figure 2). Most study participants
(n = 244; 63%) had fluctuations in hsTnI during
the 12-hour observation period, whereas hsTnI
was constantly rising in 134 (34%) participants.
Only 12 (3%) participants had steadily falling
hsTnI. The range of individual changes relative
to the overall mean hsTnI was large (from reduc-
tion by 783 ng/L to the growth by 1423 ng/L).
The Hausman test indicated that the random-
effects estimators were the most consistent and
efficient for all models. Thus, random-effects esti-
mators are reported for all models in this study
(Table 3). Results showed a significant association
between dynamic changes in SAI QRST and
hsTnI. Dynamic changes in SAI QRST and hsTnI
were concordant. Overall, a 10-fold increase in
hsTnI in a specific study participant was associ-
ated with about 8 mV*ms increase in SAI QRST
in the same participant. Accordingly, a 10-fold
decrease in hsTnI in another patient was associ-
ated with 8 mV*ms decrease in SAI QRST in that
patient.
Subgroups analyses (Figure 3 and Table 3)
showed that direct association between dynamic
changes in hsTnI and SAI QRST was especially
prominent in the ADHF group: 10-fold increase
in hsTnI in an ADHF patient was associated with
61.0 (95% CI, 5.9–116.1) mV*ms increase in SAI
QRST in that patient. Overall, adjustment by
demographic characteristics, prevalent cardiovas-
cular disease, and its risk factors did not attenu-
ate the association. However, some heterogeneity
in response was seen in ACS and cardiac-non-
ACS subgroups.
DISCUSSION
The main finding of this study is an observation
of a significant independent direct patient-specific
time-varying association between the surface
ECG scalar measure of global electrical hetero-
geneity and remodeling SAI QRST and hsTnI.
Association between SAI QRST and hsTnI was
especially prominent in ADHF, which suggest








DS (n = 316)
ANOVA/v2
P Value
Age (SD), year 62.4 (10.7) 67.7 (10.7) 61.1 (13.3) 56.4 (13.2) 0.0002
Men, n (%) 17 (60.7) 9 (47.4) 16 (45.7) 141 (44.6) 0.441
African Americans, n (%) 13 (46.4) 10 (52.6) 24 (68.6) 209 (66.1) 0.123
Hypertension, n (%) 19 (67.9) 13 (68.4) 28 (80.0) 194 (61.4) 0.161
Diabetes, n (%) 16 (57.1) 6 (31.6) 17 (48.6) 87 (27.5) 0.001
Heart failure Hx, n (%) 9 (32.1) 4 (21.1) 26 (74.3) 62 (19.6) <0.0001
Current smokers, n (%) 9 (32.1) 3 (15.8) 9 (25.7) 124 (39.2) 0.156
Current cocaine users, n (%) 1 (3.6) 0 (0) 1 (2.9) 22 (7.0) 0.657
Hypercholesterolemia, n (%) 18 (64.3) 11 (57.9) 19 (54.3) 134 (42.4) 0.059
Family Hx CHD, n (%) 11 (39.3) 6 (31.6) 14 (40.0) 112 (35.4) 0.902
Prior stroke, n (%) 6 (21.4) 1 (5.3) 4 (11.4) 46 (14.6) 0.444
Prior myocardial
infarction, n (%)
11 (39.3) 3 (15.8) 6 (17.1) 65 (20.6) 0.102
Prior revascularization, n (%) 13 (46.4) 5 (26.3) 7 (20.0) 68 (21.5) 0.026
LVH on ECG, n (%) 5 (17.9) 1 (5.3) 7 (20.0) 37 (11.71) 0.307
Right bundle brunch
block, n (%)
2 (7.1) 0 (0) 2 (5.7) 15 (4.8) 0.713
Left bundle branch block, n (%) 0 (0) 1 (5.3) 3 (8.6) 5 (1.6) 0.039
Admitted from ED, n (%) 26 (92.9) 14 (73.7) 32 (91.4) 156 (49.4) <0.0001
Baseline SAI QRST,
mV*ms (SD)
124.2 (41.7) 134.7 (48.2) 145.0 (82.8) 126.2 (52.4) 0.328











ACS = acute coronary syndrome; ADHF = acute decompensated heart failure; ECG = electrocardiographic; ED = emergency
department; SAI QRST = sum absolute QRST integral.
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that common underlying mechanisms (e.g.,
increasing wall stress, oxidative stress, neurohor-
monal activation, altered calcium handling, and
inflammation) could simultaneously affect both
ventricular conduction, remodeling and global
electrical heterogeneity (resulting in SAI QRST
change), and cardiomyocytes injury (resulting in
hsTnI change). Monitoring of ECG is a standard
of care in hospitalized ADHF patients. After
validation in another independent cohort,
dynamic monitoring of SAI QRST on ECG could
help to monitor the degree of cardiomyocyte
injury and effect of HF treatments in ADHF,
which could improve outcomes in this high-risk
population. Further prospective interventional
studies are needed to test this hypothesis.
Sum absolute QRST integral has been shown to
be associated with ventricular arrhythmia,5, 6
Figure 1. (A–C) Representative examples of 12-lead electrocardiographic (ECG) (recorded within 3 hours apart) in
acute decompensated heart failure (ADHF) patient with steadily decreasing sum absolute QRST integral (SAI QRST)
and hsTnI pattern.
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SCD,4 appropriate ICD shocks,4–6 HF outcomes,4
and mechanical response on CRT.3 Our novel
finding of the dynamic patient-specific association
of SAI QRST with hsTnI in ADHF help to under-
stand the mechanisms underlining acute changes
in SAI QRST. The nearly simultaneous dynamic
changes in SAI QRST and hsTnI suggest that they
are both governed by a similar underlining mech-
anism.
High-sensitivity troponin has been shown asso-
ciated with SCD in the general population, after
adjustment for prevalent and incident HF and
MI, and known risk factors.11 In this cohort, Kor-
ley et al.12 showed that participants with elevated
initial hsTnI but nonelevated cardiac troponin
measured by a current generation assay had a
higher risk of all-cause mortality and subsequent
cardiac hospitalizations. Mechanisms behind
hsTnI elevation in HF have been characterized in
details.16 Observed in this study nearly simulta-
neous concordant changes in SAI QRST and
hsTnI in ADHF suggest that acute dynamic
changes in the transmural wall stress, left ventric-
ular chamber size and pressure, oxidative stress,
Figure 2. “Spaghetti” plots of individual patient-specific
longitudinal relationships between log-10-transformed
sum absolute QRST integral (SAI QRST), log-10-trans-
formed hsTnI, and time, in all study participants.













Age (SD), years 55.6 (11.7) 58.2 (13.3) 57.6 (14.2) 0.457
Men, n (%) 21 (46.7) 145 (45.7) 15 (51.7) 0.962
African Americans, n (%) 29 (64.4) 203 (64.0) 19 (65.5) 0.987
Hypertension, n (%) 22 (48.9) 209 (65.9) 17 (58.6) 0.073
Diabetes, n (%) 20 (44.4) 93 (29.3) 9 (31.0) 0.123
Heart failure Hx, n (%) 11 (24.4) 81 (25.6) 5 (17.2) 0.610
Current smokers, n (%) 17 (37.8) 116 (36.6) 10 (34.5) 0.934
Current cocaine users, n (%) 3 (6.7) 17 (5.4) 4 (13.8) 0.050
Hypercholesterolemia, n (%) 18 (40.0) 148 (46.7) 13 (44.8) 0.679
Family Hx CHD, n (%) 11 (24.4) 117 (36.9) 13 (44.8) 0.157
Prior stroke, n (%) 10 (22.2) 45 (14.2) 2 (6.9) 0.172
Prior myocardial infarction, n (%) 7 (15.6) 75 (23.7) 3 (10.3) 0.141
Prior revascularization, n (%) 8 (17.8) 81 (25.6) 2 (6.9) 0.049
LVH on ECG, n (%) 3 (6.7) 44 (13.9) 2 (6.9) 0.249
Right bundle brunch block, n (%) 2 (4.44) 14 (4.42) 2 (6.90) 0.829
Left bundle branch block, n (%) 3 (6.7) 6 (1.9) 0 (0) 0.094
Admitted from ED, n (%) 17 (37.8) 187 (59.0) 19 (65.5) 0.017
Baseline SAI QRST, mV*ms (SD) 112.9 (64.1) 128.8 (53.1) 147.9 (49.4) 0.038
Baseline heart rate, bpm (SD) 81.1 (17.5) 78.5 (16.8) 79.3 (15.3) 0.630
Baseline QRS duration, ms (SD) 89.0 (26.5) 91.3 (21.0) 84.9 (23.8) 0.348
Baseline QTc, ms (SD) 430.3 (74.0) 436.3 (51.9) 418.6 (96.4) 0.338
ACS = acute coronary syndrome; ADHF = acute decompensated heart failure; ECG = electrocardiographic; ED = emergency
department; SAI QRST = sum absolute QRST integral.
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neurohormonal activation, calcium handling, and
inflammation likely cause acute remodeling (man-
ifested by serial changes in SAI QRST and hsTnI),
acute changes in the electrophysiological sub-
strate (manifested by SAI QRST dynamics), and
cardiomyocyte injury, as manifested by hsTnI.
Serial assessment of biomarkers has been
shown to inform prognosis17 in ADHF. It is
known that hsTn is useful to determine prognosis
in HF.16 Due to dynamic nature of ADHF, serial
measurements of biomarkers to guide ADHF
management are especially promising. Recent
meta-analyses18,19 showed that the use of
dynamic monitoring of biomarkers to guide HF
therapy significantly reduced mortality and HF
hospitalizations. Pivotal trial GUIDE-IT is cur-
rently ongoing to give definitive answer about
benefit of biomarker-guided HF management.20
Importantly, SAI QRST cannot be used to diag-
nose ACS, ADHF, or any other cardiac condition.
Dynamic monitoring of hsTnI is performed via
serial measurements. Unlike assessment of HF
biomarkers in the blood, continuous ECG moni-
toring is a standard of care for ADHF manage-
ment in intensive cardiac care units. Addition of
computational algorithm to calculate SAI QRST
could be easily performed, which would provide
a low-cost opportunity to noninvasively monitor
remodeling and effect of therapeutic interven-
tions in ADHF. Future studies are needed to
determine if SAI QRST-guided management of
ADHF could demonstrate improved outcomes.21
Left ventricular (LV) remodeling process is fre-
quently asymptomatic, has no specific symptoms,
and is detected by imaging studies at advanced
stage. Constantly elevated hsTnI (measured seri-
ally) over a long period of time was shown associ-
ated with deleterious LV remodeling and
provided independent risk information for poor
cardiovascular outcomes.22 Low cost of surface
ECG and dynamic SAI QRST assessment will help
to implement an idea to identify unique treat-
ment opportunities for patients with serial
changes in SAI QRST, as a step toward precision
care medicine and individualization of care.
In addition, it is possible that joint use of both
SAI QRST and hsTnI can provide complementary
prognostic value. Recent study showed that ele-
vated hsTn identified elderly individuals at high
risk for new-onset HF, particularly HF with
reduced ejection fraction,23 among study partici-
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measurement of hsTnI in a high-risk subgroup of
individuals with preexisted remodeling, as
detected by SAI QRST, might identify small sub-
group of very-high-risk persons, in whom imme-
diate intervention would be warranted. Future
randomized clinical trials are needed to test this
hypothesis.
It is important to emphasize that appropriate
statistical analytical approach should be applied
to assess dynamic changes in biomarkers. In this
study (unlike in many other previously conducted
studies of serial measurements), we used patient-
specific analytical approach, which is necessary
for appropriate patient-specific modeling and
interpretation of results. We used random-effect
estimator, which assumed that an unobserved
random component might affect association
between predictor and outcome. We performed
comprehensive adjustment for demographic char-
acteristics, presence of prevalent cardiovascular
disease, and known risk factors of cardiovascular
disease. Moreover, in model 4, we corrected for
possible endogeneity and simultaneity problems
by instrumenting endogenous variable LBBB by
prevalent cardiovascular disease and its risk fac-
tors variables. Applied analytical strategy enabled
patient-specific interpretation of serial changes in
SAI QRST and hsTnI.
Figure 3. Subgroups analysis. “Spaghetti” plots of individual patient-specific longitudinal relationships between log-
10-transformed sum absolute QRST integral (SAI QRST), log-10-transformed hsTnI and time, for each subject with (A)
acute coronary syndrome (ACS); (B) cardiac non-ACS condition; (C) acute decompensated heart failure (ADHF); and (D)
noncardiac condition.
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The fact that ECG reflects myocardial injury
has been well known for about a century. ST seg-
ment elevation is a fundamental sign of STEMI,
whereas specific dynamics of the ST segment
depression and T-wave inversion characterize
NSTEMI.24 The Selvester score25 correlates the
QRS complex morphology with the infarct size
and coronary artery lesion. In ACS patients, an
association between HsTnI and the proprietary
ECG marker CEBTM has been recently shown.13
However, elevation of hsTnI in ADHF has dif-
ferent underlying mechanisms. We observed fluc-
tuations in hsTnI and associated fluctuations in
SAI QRST over 12-hour ED observation period in
the vast majority of study participants. This wax-
ing and waning fluctuation of hsTnI and SAI
QRST is a characteristic feature of HF. Surface
ECG is a noninvasive, easily available for every-
day use tool, which recently became available on
mobile devices. Previous analysis of this ED
cohort showed that study participants with initial
hsTnI elevation above 99th% have a higher risk
of all-cause death and cardiac hospitalizations.12
Observed in this study significant dynamic associ-
ation of hsTnI with SAI QRST opens an opportu-
nity to detect progression of the myocardial
injury in HF patients early, and thus to prevent
adverse outcomes.
Use of the hsTnI (rather than hsTnT) assay is
an important strength of the study. hsTnI assay is
more sensitive than hsTnT assay and detects val-
ues in 96% of normal subjects.26 Several limita-
tions of our study have to be considered. First,
there were missing data in serial measurements
of both hsTnI and SAI QRST, and it is possible
that missing data were not at random. Second,
the size of the subgroups in this study was small.
Especially, cardiac non-ACS subgroup was small,
and the group itself was heterogeneous, and
therefore, statistical power was not sufficient to
explain weakening of the strength of association
after adjustment. However, importantly, those
limitations do not dismiss the main study finding
of the strong association between hsTnI and SAI
QRST in the whole study population, which was
especially prominent in the ADHF subgroup.
In conclusion, patient-specific time-varying
changes in the surface ECG scalar measure of
global electrical heterogeneity SAI QRST are inde-
pendently and directly associated with patient-
specific time-varying changes in hsTnI, likely
reflecting common underlying mechanisms.
Dynamic monitoring of SAI QRST on surface
ECG in ADHF could be beneficial as a noninva-
sive tool of monitoring of cardiomyocyte injury,
to guide HF management. This proof of concept
study is an important first step toward future per-
sonalized medicine.
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